| US 7,517,872 B2 | ||
| Compounds for the treatment of hepatitis C | ||
| Andrew Nickel, New Haven, Conn. (US); and John F. Kadow, Wallingford, Conn. (US) | ||
| Assigned to Bristol-Myers Squibb Company, Princeton, N.J. (US) | ||
| Filed on Feb. 15, 2008, as Appl. No. 12/31,844. | ||
| Claims priority of provisional application 60/891049, filed on Feb. 22, 2007. | ||
| Prior Publication US 2008/0206191 A1, Aug. 28, 2008 | ||
| Int. Cl. A61P 31/00 (2006.01); A61K 31/55 (2006.01); C07D 223/14 (2006.01) | ||
| U.S. Cl. 514—214.01 [540/576] | 13 Claims |
1. A compound of formula I
 where:
R1 is H, CO2R5 or CONR6R7;
R2 is hydroxy, alkoxy, amino, alkylamino, dialkylamino;
or R2 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, or homomorpholinyl, and is substituted
with 0-3 substituents selected from alkyl and alkoxy;
or R2 is
 R3 is hydrogen, halo, alkyl, alkenyl, hydroxy, benzyloxy, or alkoxy;
R4 is cycloalkyl;
R5 is hydrogen or alkyl;
R6 is hydrogen, alkyl, alkylSO2, cycloalkylSO2, haloalkylSO2, (R8)2NSO2, or (R9)SO2;
R7 is hydrogen or alkyl;
R8 is hydrogen or alkyl;
R9 is azetidinyl, pyrrolidinyl, piperidinyl, N-(R10)piperazinyl, morpholinyl, thiomorpholinyl, homopiperidinyl, or homomorpholinyl;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, cycloalkyl, (cycloalkyl)alkyl, benzyl, alkylcarbonyl, alkoxycarbonyl, benzyloxycarbonyl, (R8)2NCO, alkylSO2, or pyridinyl; and
X is absent (forming a compound of formula Ia), a bond (forming a compound of formula Ib), or methylene (forming a compound
of formula Ic);
 |